FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041526044> ?p ?o ?g. }

• W2041526044 endingPage "100" @default.
• W2041526044 startingPage "100" @default.
• W2041526044 abstract "Objective: To examine the effect of acyclovir use on disease progression and survival in human immunodeficiency virus (HIV)-seropositive persons treated with zidovudine. Setting: Four university-based or -affiliated clinics. Design: Prospective cohort study of homosexual and bisexual men with semi-annual follow-up. Intent-to-treat Cox models were fit to determine the relation between the use of acyclovir (modeled as a time-dependent covariate) and disease progression, controlling for baseline and time-dependent clinical and laboratory prognostic variables. The acquired immunodeficiency syndrome (AIDS)-free duration and survival time were calculated from the first use of zidovudine. Analysis included study visits 7 to 17 (from 1987 to 1992). Patients: 786 HIV-seropositive participants in the Multicenter AIDS Cohort Study who began zidovudine therapy before a clinical diagnosis of AIDS; of these, 515 subsequently received acyclovir. Participants were asked at each visit whether they had “used any medication for health reasons not related to AIDS or if they had taken any medication to help fight AIDS or the HIV virus”; 488 patients indicated acyclovir use under either or both questions, and 242 patients indicated only the latter use. Results: The use of acyclovir for any indication was not associated with an effect on progression to AIDS but was associated with a 26% decrease in the risk for death (relative hazard, 0.74; P = 0.07). The use of acyclovir for HIV infection was also not associated with an effect on progression to AIDS but was associated with a 36% decrease in the risk for death (relative hazard, 0.64; P = 0.01). To further investigate these findings, we examined dose, constancy, and timing of acyclovir use. The median daily dose of acyclovir used for HIV infection was between 600 and 800 mg. No apparent dose effect on survival was found. Longer uninterrupted use of acyclovir for any indication was associated with an 18% decrease in the risk for death for three or more consecutive visits (relative hazard, 0.82; P = 0.23), a 28% decrease for four or more consecutive visits (relative hazard, 0.72; P = 0.09), and a 7% decrease per visit based on the cumulative number of visits while the patient received acyclovir (relative hazard, 0.93 per visit increase; P = 0.03). Use of acyclovir for any indication and use of acyclovir for HIV infection were each associated with a 44% decreased probability of death if the drug was used after AIDS developed (P = 0.007 and P = 0.005, respectively) but not before. To further investigate the prolongation of survival, two landmark analyses were done. The first analysis began at a landmark of 1 year after initiation of zidovudine therapy and compared three groups of patients: those who used acyclovir at or before this landmark, those who had never started acyclovir or started the drug after the landmark, and those who had never used acyclovir. The 90% survival times were 1325, 1059, and 982 days, respectively. The second analysis began at a landmark of developing either a CD4 count less than 50 cells/µL or clinical AIDS. The 90% survival times for the three groups were 398, 261, and 176 days, respectively. Conclusions: Our analysis suggests that consistent use of acyclovir at a dose sufficient to suppress herpetic recurrences (that is, 600 to 800 mg/d) has a clinically significant effect on prolonging survival in a well-characterized cohort with extensive previous exposure to herpesvirus infections. Further clinical investigation of low-dose acyclovir with concomitant antiretroviral therapy is warranted." @default.
• W2041526044 created "2016-06-24" @default.
• W2041526044 creator A5018847170 @default.
• W2041526044 creator A5026772130 @default.
• W2041526044 creator A5029043155 @default.
• W2041526044 creator A5030784114 @default.
• W2041526044 creator A5033398725 @default.
• W2041526044 creator A5060329768 @default.
• W2041526044 creator A5077395512 @default.
• W2041526044 creator A5082899242 @default.
• W2041526044 date "1994-07-15" @default.
• W2041526044 modified "2023-10-18" @default.
• W2041526044 title "The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival: Analysis of Data in the Multicenter AIDS Cohort Study" @default.
• W2041526044 doi "https://doi.org/10.7326/0003-4819-121-2-199407150-00004" @default.
• W2041526044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8017721" @default.
• W2041526044 hasPublicationYear "1994" @default.
• W2041526044 type Work @default.
• W2041526044 sameAs 2041526044 @default.
• W2041526044 citedByCount "63" @default.
• W2041526044 countsByYear W20415260442012 @default.
• W2041526044 countsByYear W20415260442018 @default.
• W2041526044 countsByYear W20415260442019 @default.
• W2041526044 countsByYear W20415260442020 @default.
• W2041526044 crossrefType "journal-article" @default.
• W2041526044 hasAuthorship W2041526044A5018847170 @default.
• W2041526044 hasAuthorship W2041526044A5026772130 @default.
• W2041526044 hasAuthorship W2041526044A5029043155 @default.
• W2041526044 hasAuthorship W2041526044A5030784114 @default.
• W2041526044 hasAuthorship W2041526044A5033398725 @default.
• W2041526044 hasAuthorship W2041526044A5060329768 @default.
• W2041526044 hasAuthorship W2041526044A5077395512 @default.
• W2041526044 hasAuthorship W2041526044A5082899242 @default.
• W2041526044 hasConcept C10515644 @default.
• W2041526044 hasConcept C126322002 @default.
• W2041526044 hasConcept C187212893 @default.
• W2041526044 hasConcept C188816634 @default.
• W2041526044 hasConcept C201903717 @default.
• W2041526044 hasConcept C203014093 @default.
• W2041526044 hasConcept C207103383 @default.
• W2041526044 hasConcept C2776452011 @default.
• W2041526044 hasConcept C2779127605 @default.
• W2041526044 hasConcept C2779898580 @default.
• W2041526044 hasConcept C2780216070 @default.
• W2041526044 hasConcept C2780727368 @default.
• W2041526044 hasConcept C3013748606 @default.
• W2041526044 hasConcept C44249647 @default.
• W2041526044 hasConcept C50382708 @default.
• W2041526044 hasConcept C71924100 @default.
• W2041526044 hasConcept C72563966 @default.
• W2041526044 hasConceptScore W2041526044C10515644 @default.
• W2041526044 hasConceptScore W2041526044C126322002 @default.
• W2041526044 hasConceptScore W2041526044C187212893 @default.
• W2041526044 hasConceptScore W2041526044C188816634 @default.
• W2041526044 hasConceptScore W2041526044C201903717 @default.
• W2041526044 hasConceptScore W2041526044C203014093 @default.
• W2041526044 hasConceptScore W2041526044C207103383 @default.
• W2041526044 hasConceptScore W2041526044C2776452011 @default.
• W2041526044 hasConceptScore W2041526044C2779127605 @default.
• W2041526044 hasConceptScore W2041526044C2779898580 @default.
• W2041526044 hasConceptScore W2041526044C2780216070 @default.
• W2041526044 hasConceptScore W2041526044C2780727368 @default.
• W2041526044 hasConceptScore W2041526044C3013748606 @default.
• W2041526044 hasConceptScore W2041526044C44249647 @default.
• W2041526044 hasConceptScore W2041526044C50382708 @default.
• W2041526044 hasConceptScore W2041526044C71924100 @default.
• W2041526044 hasConceptScore W2041526044C72563966 @default.
• W2041526044 hasIssue "2" @default.
• W2041526044 hasLocation W20415260441 @default.
• W2041526044 hasLocation W20415260442 @default.
• W2041526044 hasOpenAccess W2041526044 @default.
• W2041526044 hasPrimaryLocation W20415260441 @default.
• W2041526044 hasRelatedWork W2010288878 @default.
• W2041526044 hasRelatedWork W2010916963 @default.
• W2041526044 hasRelatedWork W2055733835 @default.
• W2041526044 hasRelatedWork W2066920818 @default.
• W2041526044 hasRelatedWork W2109259850 @default.
• W2041526044 hasRelatedWork W2111449967 @default.
• W2041526044 hasRelatedWork W2143414727 @default.
• W2041526044 hasRelatedWork W2410416692 @default.
• W2041526044 hasRelatedWork W76273905 @default.
• W2041526044 hasRelatedWork W2488499266 @default.
• W2041526044 hasVolume "121" @default.
• W2041526044 isParatext "false" @default.
• W2041526044 isRetracted "false" @default.
• W2041526044 magId "2041526044" @default.
• W2041526044 workType "article" @default.